LongBio Pharma AGM Ratifies 2025 Financials and Grants New Capital Mandates

Bulletin Express06-30

LongBio Pharma (Suzhou) Co., Ltd. reported that all five resolutions tabled at its 30 June 2026 annual general meeting were approved by poll, confirming broad shareholder support for the company’s 2025 financials, dividend proposal, auditor re-appointment, and refreshed capital mandates.

Shareholder turnout reached 59.32%, with 44.01 million shares voting out of 74.19 million issued.

1. 2025 Accountant’s Report & Profit Distribution • Both items secured unanimous backing, receiving 100.00% of the votes cast.

2. Auditor Re-appointment • Ernst & Young was re-appointed for the 2026 financial year with 100.00% support; the board is authorised to fix remuneration.

3. General Mandates • Issuance mandate: approved by 98.52% of votes, allowing the board to issue new shares up to the prescribed limit. • H-share repurchase mandate: passed with 100.00% approval, permitting market buybacks within regulatory caps.

No shareholders were required to abstain, and none voted against any ordinary resolutions. Tricor Investor Services and two shareholder representatives acted as scrutineers. All directors attended the meeting, ensuring compliance with the Company Law and the Articles of Association.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173293167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173293167","market":"hk","top_or_hot":-1,"title":"LongBio Pharma AGM Ratifies 2025 Financials and Grants New Capital Mandates","media":"Bulletin Express","content":"<p>LongBio Pharma (Suzhou) Co., Ltd. reported that all five resolutions tabled at its 30 June 2026 annual general meeting were approved by poll, confirming broad shareholder support for the company’s 2025 financials, dividend proposal, auditor re-appointment, and refreshed capital mandates.</p>\n<p>Shareholder turnout reached 59.32%, with 44.01 million shares voting out of 74.19 million issued.</p>\n<p>1. 2025 Accountant’s Report & Profit Distribution  \n   • Both items secured unanimous backing, receiving 100.00% of the votes cast.</p>\n<p>2. Auditor Re-appointment  \n   • Ernst & Young was re-appointed for the 2026 financial year with 100.00% support; the board is authorised to fix remuneration.</p>\n<p>3. General Mandates  \n   • Issuance mandate: approved by 98.52% of votes, allowing the board to issue new shares up to the prescribed limit.  \n   • H-share repurchase mandate: passed with 100.00% approval, permitting market buybacks within regulatory caps.</p>\n<p>No shareholders were required to abstain, and none voted against any ordinary resolutions. Tricor Investor Services and two shareholder representatives acted as scrutineers. All directors attended the meeting, ensuring compliance with the Company Law and the Articles of Association.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LongBio Pharma AGM Ratifies 2025 Financials and Grants New Capital Mandates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongBio Pharma AGM Ratifies 2025 Financials and Grants New Capital Mandates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-30 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LongBio Pharma (Suzhou) Co., Ltd. reported that all five resolutions tabled at its 30 June 2026 annual general meeting were approved by poll, confirming broad shareholder support for the company’s 2025 financials, dividend proposal, auditor re-appointment, and refreshed capital mandates.</p>\n<p>Shareholder turnout reached 59.32%, with 44.01 million shares voting out of 74.19 million issued.</p>\n<p>1. 2025 Accountant’s Report & Profit Distribution  \n   • Both items secured unanimous backing, receiving 100.00% of the votes cast.</p>\n<p>2. Auditor Re-appointment  \n   • Ernst & Young was re-appointed for the 2026 financial year with 100.00% support; the board is authorised to fix remuneration.</p>\n<p>3. General Mandates  \n   • Issuance mandate: approved by 98.52% of votes, allowing the board to issue new shares up to the prescribed limit.  \n   • H-share repurchase mandate: passed with 100.00% approval, permitting market buybacks within regulatory caps.</p>\n<p>No shareholders were required to abstain, and none voted against any ordinary resolutions. Tricor Investor Services and two shareholder representatives acted as scrutineers. All directors attended the meeting, ensuring compliance with the Company Law and the Articles of Association.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01779","symbol_name":"天辰生物-B","start_time":0,"source_url":"","article_id":"1173293167","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173293167","pubTimestamp":1782830681,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"LongBio Pharma (Suzhou) Co., Ltd. reported that all five resolutions tabled at its 30 June 2026 annual general meeting were approved by poll, confirming broad shareholder support for the company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01779":"天辰生物-B"},"translate_title":"LongBio Pharma年度股东大会批准2025年财务并授予新的资本授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01779":1},"content_text":"LongBio Pharma (Suzhou) Co., Ltd. reported that all five resolutions tabled at its 30 June 2026 annual general meeting were approved by poll, confirming broad shareholder support for the company’s 2025 financials, dividend proposal, auditor re-appointment, and refreshed capital mandates.\nShareholder turnout reached 59.32%, with 44.01 million shares voting out of 74.19 million issued.\n1. 2025 Accountant’s Report & Profit Distribution  \n   • Both items secured unanimous backing, receiving 100.00% of the votes cast.\n2. Auditor Re-appointment  \n   • Ernst & Young was re-appointed for the 2026 financial year with 100.00% support; the board is authorised to fix remuneration.\n3. General Mandates  \n   • Issuance mandate: approved by 98.52% of votes, allowing the board to issue new shares up to the prescribed limit.  \n   • H-share repurchase mandate: passed with 100.00% approval, permitting market buybacks within regulatory caps.\nNo shareholders were required to abstain, and none voted against any ordinary resolutions. Tricor Investor Services and two shareholder representatives acted as scrutineers. All directors attended the meeting, ensuring compliance with the Company Law and the Articles of Association.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173293167","isCrawlerRequest":true}